title: Results of long-term follow-up after treatment of central precocious puberty with leuprorelin acetate: evaluation of effectiveness of treatment and recovery of gonadal function. The TAP-144-SR Japanese Study Group on Central Precocious Puberty.
abstract: We evaluated the effect of leuprorelin treatment on adult height (AH) and followed recovery of reproductive function in 63 girls and 13 boys with central precocious puberty (CPP). Mean treatment durations were 3.8 +/- 2.0 and 4.1 +/- 2.5 yr, and posttreatment follow-up durations were 3.5 +/- 1.3 and 2.6 +/- 1.1 yr for girls and boys, respectively. AH was 154.5 +/- 5.7 cm for girls, and 89.5% of girls reached AH within their target height range. For boys, AH was 163.2 +/- 13.0 cm, and 90.9% reached target height range. It appeared that the Bayley-Pinneau method, modified for Japanese children, using a table for advanced bone age (BA), overestimated AH in CPP; and this method, using a table for average BA and projected height for BA, was suitable for prediction of AH in CPP. Menarche or remenarche occurred in 96.8% of girls at the age of 13.1 +/- 1.5 yr. Of 11 girls who contributed urine samples, all seven idiopathic and two organic cases were considered to have ovulation. Serum testosterone levels reached normal adult level in all boys. In conclusion, long-term leuprorelin treatment for children with CPP improved AH and had no adverse effects on recovery of reproductive function.
authors.affiliation: Department of Endocrinology and Metabolism, National Center for Child Health and Development, 2-10-1, Okura, Setagaya, Tokyo, 157-8535, Japan. tanaka-t@ncchd.go.jp
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Tanaka
authors.forename: Hiroo
authors.initials: H
authors.lastname: Niimi
authors.forename: Nobutake
authors.initials: N
authors.lastname: Matsuo
authors.forename: Kenji
authors.initials: K
authors.lastname: Fujieda
authors.forename: Katsuhiko
authors.initials: K
authors.lastname: Tachibana
authors.forename: Kenji
authors.initials: K
authors.lastname: Ohyama
authors.forename: Mari
authors.initials: M
authors.lastname: Satoh
authors.forename: Koji
authors.initials: K
authors.lastname: Kugu
mesh_terms: D000293:Adolescent; D000328:Adult; D001827:Body Height; D002648:Child; D005260:Female; D005300:Fertility Agents, Female / Q000008:administration & dosage* / Q000009:adverse effects; D005500:Follow-Up Studies; D006801:Humans; D007564:Japan; D016729:Leuprolide / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008572:Menarche / Q000187:drug effects; D010060:Ovulation / Q000187:drug effects; D011446:Prospective Studies; D011629:Puberty, Precocious / Q000188:drug therapy*; D020127:Recovery of Function / Q000187:drug effects
chemical_list: D005300:Fertility Agents, Female; D016729:Leuprolide